Study S000993

Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT03590626
Acronym: D-LIFT
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Masking: SINGLE
Status: COMPLETED
Enrollment: 60
Start: 2019-01-01
Primary completion: 2020-01-14
Lead sponsor: Medanta, The Medicity, India
Conditions: Non Alcoholic Fatty Liver Disease; Type2 Diabetes Mellitus
Interventions: DRUG:Dulaglutide
Results posted: FALSE

Registered primary outcomes

Change in liver fat [Baseline to 24 weeks]

Linked records (7)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0016566	Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Kuchay MS, Diabetologia	2020	Randomized trial	PMID 32865597 DOI	cites ClinicalTrials.gov:NCT03590626; registry reference DERIVED:32865597
R0022270	Effect of Liraglutide Therapy on Liver Fat Content in Patients With Inadequately Controlled Type 2 Diabetes: The Lira-NAFLD Study. Petit JM, The Journal of clinical endocrinology and metabolism	2017	Other trial	PMID 27732328 DOI	registry reference RESULT:27732328
R0025603	Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial. Bouchi R, Endocrine journal	2017	Randomized trial	PMID 27916783 DOI	registry reference RESULT:27916783
R0015848	Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). Giorgino F, Diabetes care	2015	Randomized trial	PMID 26089386 DOI	registry reference RESULT:26089386
R0016652	Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Nauck M, Diabetes care	2014	Randomized trial	PMID 24742660 DOI	registry reference RESULT:24742660
R0020934	Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Dungan KM, Lancet (London, England)	2014	Randomized trial	PMID 25018121 DOI	registry reference RESULT:25018121
R0022865	Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Umpierrez G, Diabetes care	2014	Randomized trial	PMID 24842985 DOI	registry reference BACKGROUND:24842985